Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Marlene Resch"'
Autor:
Elisabeth Gludovacz, Kornelia Schuetzenberger, Marlene Resch, Katharina Tillmann, Karin Petroczi, Markus Schosserer, Sigrid Vondra, Serhii Vakal, Gerald Klanert, Jürgen Pollheimer, Tiina A Salminen, Bernd Jilma, Nicole Borth, Thomas Boehm
Publikováno v:
eLife, Vol 10 (2021)
Background: Excessive plasma histamine concentrations cause symptoms in mast cell activation syndrome, mastocytosis, or anaphylaxis. Anti-histamines are often insufficiently efficacious. Human diamine oxidase (hDAO) can rapidly degrade histamine and
Externí odkaz:
https://doaj.org/article/d7281aa1f5af4be284b2a714515c12fb
Autor:
Elisabeth Gludovacz, Marlene Resch, Kornelia Schuetzenberger, Karin Petroczi, Daniel Maresch, Stefan Hofbauer, Bernd Jilma, Nicole Borth, Thomas Boehm
Publikováno v:
Glycobiology. 32(5)
Elevated plasma and tissues histamine concentrations can cause severe symptoms in mast cell activation syndrome, mastocytosis or anaphylaxis. Endogenous and recombinant human diamine oxidase (rhDAO) can rapidly and completely degrade histamine, and a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b4667c88c2884d23a12a7418125b193
https://pubmed.ncbi.nlm.nih.gov/35088086
https://pubmed.ncbi.nlm.nih.gov/35088086
Autor:
Tiina A. Salminen, Kornelia Schuetzenberger, Bernd Jilma, Elisabeth Gludovacz, Gerald Klanert, Serhii Vakal, Sigrid Vondra, Karin Petroczi, Katharina Tillmann, Thomas Boehm, Marlene Resch, Jürgen Pollheimer, Markus Schosserer, Nicole Borth
Publikováno v:
eLife
eLife, Vol 10 (2021)
eLife, Vol 10 (2021)
Background:Excessive plasma histamine concentrations cause symptoms in mast cell activation syndrome, mastocytosis, or anaphylaxis. Anti-histamines are often insufficiently efficacious. Human diamine oxidase (hDAO) can rapidly degrade histamine and t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4311f9d344ff1f189cd23ab92ae08515
https://doi.org/10.7554/elife.68542
https://doi.org/10.7554/elife.68542
Autor:
Marlene Resch, Sigrid Vondra, Nikolaus Virgolini, Thomas Boehm, Nicole Borth, Karin Petroczi, Elisabeth Gludovacz, Bernd Jilma, Serhii Vakal, Kornelia Schuetzenberger, Tiina A. Salminen, Jürgen Pollheimer, Markus Schosserer, Katharina Tillmann
Publikováno v:
Glycobiology. 31(4)
Human diamine oxidase (hDAO) rapidly inactivates histamine by deamination. No pharmacokinetic data are available to better understand its potential as a new therapeutic modality for diseases with excess local and systemic histamine, like anaphylaxis,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e2c9f609b585d05f9d314f4f93dbab6f
https://pubmed.ncbi.nlm.nih.gov/32985651
https://pubmed.ncbi.nlm.nih.gov/32985651
Publikováno v:
Laboratory animals. 53(2)
Intravenous (IV) administration in mice is predominantly performed via the lateral tail veins. The technique requires adequate training before it can be used safely and routinely. A novel anaesthesia induction chamber has been developed to simplify t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f526f7e7c8cd6bfcddfd1dd52a36015
https://pubmed.ncbi.nlm.nih.gov/30089439
https://pubmed.ncbi.nlm.nih.gov/30089439
Autor:
Sylvia Tippl, Alexander Bauer, Friedrich Scheiflinger, Marlene Resch, Christina Piskernik, Peter Leidenmuehler, Dagmar Verdino, Sabine Knappe, Werner Hoellriegl, Michael Dockal
Publikováno v:
Blood. 122:2353-2353
Treatment of hemophilia A is complicated by development of FVIII neutralizing antibodies, which occurs in ∼30% of patients with severe hemophilia A. Acute bleeds in inhibitor patients can be treated with the available bypassing agents, activated pr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0f9ba4d1b33fba358ee58d334e5a2021
https://doi.org/10.1182/blood.v122.21.2353.2353
https://doi.org/10.1182/blood.v122.21.2353.2353
Autor:
Eva-Maria Muchitsch, Werner Hoellriegl, Alexandra Schiviz, Hans Peter Schwarz, Marlene Resch, Hanspeter Rottensteiner, Elisa Farnleitner, Friedrich Scheiflinger
Publikováno v:
Blood. 120:2216-2216
Abstract 2216 Baxter is currently developing a recombinant ADAMTS13 (rADAMTS13, a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13) product for potential prophylaxis and treatment of thrombotic thrombocytopenic purpura
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::85c5b184b9a08222f94da95751c3348a
https://doi.org/10.1182/blood.v120.21.2216.2216
https://doi.org/10.1182/blood.v120.21.2216.2216
Autor:
Alexandra Schiviz, Marlene Resch, Hartmut J. Ehrlich, Eva-Maria Muchitsch, John-Philip Lawo, Bettina Bischetsrieder, Friedrich Scheiflinger, Werner Hoellriegl, Peter Leidenmuehler, Hans Peter Schwarz
Publikováno v:
Blood. 116:4659-4659
Abstract 4659 Baxter has developed a recombinant FVIIa (rFVIIa) product for the treatment of patients with hemophilia A and hemophilia B with inhibitors. The aim of the presented preclinical studies was to evaluate the efficacy of Baxter's rFVIIa. Fo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c46501e9543093d3c56331a40ea2c884
https://doi.org/10.1182/blood.v116.21.4659.4659
https://doi.org/10.1182/blood.v116.21.4659.4659